Larimar Therapeutics (NASDAQ:LRMR) Stock Price Crosses Above Fifty Day Moving Average – Should You Sell?

Larimar Therapeutics, Inc. (NASDAQ:LRMR – Get Free Report) shares crossed above its 50-day moving average during trading on Friday. The stock has a 50-day moving average of $2.93 and traded as high as $3.08. Larimar Therapeutics shares last traded at $3.02, with a volume of 2,531,459 shares changing hands.

Key Headlines Impacting Larimar Therapeutics

These are some of the LRMR headlines that stood out recently:

  • Positive Sentiment: CEO Carole Ben-Maimon, CFO Michael Celano, COO John B. Jr. Harlow, insider Gopi Shankar, and directors Frank Thomas and Joseph Truitt together purchased 52,810 shares for roughly $195,000. Director Thomas Hamilton separately bought 70,000 shares for $186,900. Insider purchase report Hamilton SEC filing
  • Neutral Sentiment: The supplied coverage also notes H.C. Wainwright maintained a Buy rating; no rating change or fresh price-moving catalyst was reported. Analyst rating report

Analyst Ratings Changes

LRMR has been the topic of several research analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Larimar Therapeutics in a research report on Thursday, October 15th. Wall Street Zen cut shares of Larimar Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday. Wedbush restated an “outperform” rating on shares of Larimar Therapeutics in a research report on Tuesday. Finally, Leerink Partners assumed coverage on Larimar Therapeutics in a report on Monday, September 14th. They issued an “outperform” rating and a $13.00 price objective for the company. Two research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $10.33.

Check Out Our Latest Report on Larimar Therapeutics

Larimar Therapeutics Stock Performance

The firm has a 50-day moving average of $2.93 and a 200-day moving average of $3.76. The firm has a market capitalization of $313.72 million, a P/E ratio of -1.55 and a beta of 0.73.

Insider Activity

In other news, CFO Michael Celano bought 18,460 shares of the firm’s stock in a transaction that occurred on Wednesday, November 11th. The shares were bought at an average cost of $2.71 per share, with a total value of $50,026.60. Following the completion of the purchase, the chief financial officer directly owned 234,245 shares in the company, valued at $634,803.95. This represents a 8.55% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at this link. Also, COO John B. Jr. Harlow purchased 17,800 shares of the stock in a transaction that occurred on Wednesday, November 11th. The shares were purchased at an average price of $2.80 per share, with a total value of $49,840.00. Following the completion of the acquisition, the chief operating officer directly owned 67,800 shares in the company, valued at $189,840. The trade was a 35.60% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders purchased 140,810 shares of company stock valued at $381,955 in the last three months. Corporate insiders own 4.00% of the company’s stock.

Hedge Funds Weigh In On Larimar Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of LRMR. Marshall Wace LLP grew its stake in shares of Larimar Therapeutics by 9.1% in the third quarter. Marshall Wace LLP now owns 2,195,954 shares of the company’s stock worth $7,005,000 after purchasing an additional 183,496 shares during the last quarter. Empowered Funds LLC bought a new position in Larimar Therapeutics during the 3rd quarter valued at approximately $268,000. Blue Owl Capital Holdings LP raised its position in Larimar Therapeutics by 0.3% during the 3rd quarter. Blue Owl Capital Holdings LP now owns 9,923,904 shares of the company’s stock valued at $31,707,000 after purchasing an additional 32,147 shares during the last quarter. AIGH Capital Management LLC bought a new position in Larimar Therapeutics during the 3rd quarter valued at approximately $5,911,000. Finally, WINTON GROUP Ltd purchased a new stake in Larimar Therapeutics in the 2nd quarter worth approximately $160,000. 91.92% of the stock is owned by institutional investors.

Larimar Therapeutics Company Profile

(Get Free Report)

Larimar Therapeutics, Inc. is a clinical-stage biotechnology company headquartered in Bala Cynwyd, Pennsylvania, focused on developing treatments for rare diseases. Its lead drug candidate is nomlabofusp, formerly known as CTI-1601, an engineered fusion protein designed to deliver frataxin to mitochondria. Nomlabofusp is being developed to treat Friedreich’s ataxia, a rare, inherited neurodegenerative disorder associated with insufficient frataxin. Larimar’s approach uses a cell-penetrating peptide to transport frataxin into cells and mitochondria, with the goal of addressing an underlying cause of the disease rather than only treating its symptoms.

Recommended Stories

Receive News & Ratings for Larimar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Larimar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.